Who is sponsoring NCT04350086?

NCT04350086 is sponsored by University Hospital, Limoges.

What drugs are being tested in NCT04350086?

Interventions in NCT04350086: Treatment with Dexmedetomidine.

What condition does NCT04350086 study?

NCT04350086 studies COVID-19 Infection, Sars-cov-2, Respiratory Failure, Palliative Situation.

Is NCT04350086 still recruiting?

NCT04350086 is currently withdrawn. Last updated 2 September 2020.

Last reviewed 2020-09-02 · How we verify

NCT04350086: PRODEX

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Use of Dexmedetomidine in Light to Moderate Sedation in the Patient in the Palliative Situation of a Sars-cov-2 / COVID-19 Infection

Withdrawn Phase 4 Last updated 2 September 2020

What this trial tests

Phase 4 trial testing Treatment with Dexmedetomidine in COVID-19 Infection. Withdrawn.

Timeline

20 April 2020

Primary endpoint
20 November 2020

20 November 2020

Quick facts

Lead sponsor	University Hospital, Limoges
Phase	Phase 4
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	20 April 2020
Primary completion	20 November 2020
Estimated completion	20 November 2020
Sites	1 location across France

Drugs / interventions tested

Treatment with Dexmedetomidine — full drug profile →

Conditions studied

COVID-19 Infection — all drugs for COVID-19 Infection →
Sars-cov-2 — all drugs for Sars-cov-2 →
Respiratory Failure — all drugs for Respiratory Failure →
Palliative Situation — all drugs for Palliative Situation →

Sponsor

University Hospital, Limoges

Who can join

18 and older, any sex, with COVID-19 Infection or Sars-cov-2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The current sars-cov-2 epidemic is responsible for severe respiratory infections leading to end-of-life situations. Dexmedetomidine may be indicated in mild to moderate sedation in palliative patients, due to its pharmacological characteristics. The hypothesis of this study is that Dexmedetomidine would allow effective and safe light sedation in patients with respiratory failure in palliative situations suffering from Covid-19 infection.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.
Jafarzadeh A, Chauhan P, Saha B, Jafarzadeh S, et al · · 2020 · cited 246× · PMID 32687918 · DOI 10.1016/j.lfs.2020.118102
Dexmedetomidine: another arrow in the quiver to fight COVID-19 in intensive care units.
Jain A, Lamperti M, Doyle DJ. · · 2021 · cited 13× · PMID 33190859 · DOI 10.1016/j.bja.2020.10.010
Dexmedetomidine does not directly inhibit neutrophil extracellular trap production.
Corriden R, Schmidt BE, Olson J, Okerblom J, et al · · 2022 · cited 4× · PMID 34916052 · DOI 10.1016/j.bja.2021.11.015
SARS-Cov-2: Biology, Detection, Macrophage Mediated Pathogenesis and Potential Treatments.
Borges-Velez G, Rosario-Rodriguez LJ, Rosado-Philippi JE, Cartagena LJ, et al · · 2020 · cited 3× · PMID 34485853 · DOI 10.23880/vij-16000242
Dexmedetomidine in COVID-19: probing promises with prudence!
Magoon R. · · 2021 · cited 1× · PMID 33168381 · DOI 10.1016/j.ajem.2020.10.034

Verify or expand the search:

Other recruiting trials for COVID-19 Infection

Currently open trials in the same condition.

NCT07013474 — A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised · Phase 3 · recruiting
NCT06965751 — A Study on the Effects in Healthy People of a New Drug Called PDI204 for Treating COVID-19 · Phase 1 · active not recruiting
NCT06923137 — A Study to Learn About How Well Yearly Updates to the COVID-19 Vaccine Work to Protect People From COVID-19 and How Much · active not recruiting
NCT05672355 — A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia · Phase 2 · recruiting
NCT05774093 — Evaluation of COVID-19 Immune Barrier and Reinfection Risk · recruiting

Other University Hospital, Limoges trials

Trials by the same sponsor.

NCT07407101 — Impact of Filtration on Autologous Serum Eye Drops · NA · not yet recruiting
NCT07406425 — Evaluation of Efficacy of Coconut Oil Mouth Care for Non-autonomous Hospitalised Elderly People. · NA · not yet recruiting
NCT07436780 — B Lymphocyte Populations in the Pulmonary Microenvironment of Patients Under Mechanical Ventilation With or Without VAP · not yet recruiting
NCT07331298 — Apparent Diffusion Coefficient of the Intervertebral Disc in Children: Pilot Study · not yet recruiting
NCT07019818 — Esmolol Versus Sufentanil on the Quality of Post-cholecystectomy Recovery Laparoscopic Anaesthesia With Orotracheal Intu · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04350086 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Hospital, Limoges
Last refreshed: 2 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04350086.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing